P024 KEYNOTE-937 trial in progress: adjuvant pembrolizumab for hepatocellular carcinoma and complete radiologic response after surgical resection or local ablation

Introduction

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths worldwide. Surgical resection and local ablation are potentially curative options for patients with HCC; however, tumor recurrence is not uncommon. The lack of a standard-of-care adjuvant therapy for HCC highlights an urgent therapeutic need to prevent disease recurrence and improve overall survival. Pembrolizumab, a PD-1 inhibitor, has shown...